(place patient label here) Patient Name: Order Set Directions: > (√)- Check orders to activate; Orders with pre-checked box ☑ will be followed unless lined out. > Initial each place in the pre-printed order set where changes such as additions, deletions or line outs have been made > Initial each page and Sign/Date/Time last page	BENEFIS HEALTH SYSTEM Benefis HOSPITALS PROVIDER ORDERS
Diagnosis:	
llergies with reaction type:	
NICU PIV Extravasation Version 1	Approved 03/28/2013
Nursing Orders ☐ Communication order: Refer to Neonatal Peripheral Intravenous Extravasati ☐ Elevate extremity affected as able; do not apply heat Medications ☐ Patient Weight: Extravasation of HYPEROSMOLAR agents: (Stage 3-4) hyaluronidase, human recombinant 150 unit/mL injection (HYLENEX) ☐ 150 unit subcutaneously Administer in separate 30 unit (0.2 milliliter) injections into the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the second content of the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the reference in the extravasation site at the leading edge changing the re	injections for up to a total of 5
 Extravasation of VASOCONSTRICTOR agents: (Stage 3-4) For infants LESS than 2.5 kilogram SELECT: phentolamine 0.25 milligram/milliliter injection (REGITINE) 0.125 milligram subcutaneously Administer in separate 0.025 milligram a total of 5 injections into the extravasation site at the leading edge chainjection For infants GREATER than or equal to 2.5 kilogram SELECT: phentolamine 0.25 milligram/milliliter injection (REGITINE) 0.25 milligram subcutaneously Administer in separate 0.05 milligram (total of 5 injections into the extravasation site at the leading edge chaninjection 	anging the needle with each 0.2 milliliter) injections for up to a